Suppr超能文献

白花丹素:未来研究与开发的潜在候选者。

Plumbagin: A Potential Candidate for Future Research and Development.

机构信息

Department of Pharmaceutical Quality Assurance, SSR College of Pharmacy, Sayli Silvassa, India.

出版信息

Curr Pharm Biotechnol. 2022;23(15):1800-1812. doi: 10.2174/1389201023666211230113146.

Abstract

Plumbagin has gained a lot of attention in research due to its various therapeutic actions. It is a secondary metabolite obtained from different plant families, such as Plumbaginaceae, Droseraceae, and Ebenceae. Various studies on plumbagin have revealed that it is a natural gift for mankind in treating chronic diseases, like cancer, diabetes, malaria, bacterial infection, and controlling cardiovascular disease. However, there are several challenges in developing plumbagin as a therapeutic agent. The first and foremost is its limited solubility and oral bioavailability. The second limitation is its toxicity. Plumbagin has a narrow therapeutic window, and literature reveals that the compound has moderate toxicity in animals. However, data are insufficient to prove that plumbagin is unsafe for humans. Despite the many therapeutic benefits of plumbagin, it remains unexploited for mankind. Thus, a systematic review of its toxicity, pharmacology, and safety is required to be performed. This review work signifies the depth of therapeutic applications proven via research, its different modes of isolation and separation of chemical constituents, and its modification. A thorough review of promising therapeutic targets via docking studies is also presented. Different methods used to quantify plumbagin from the plant are reviewed. An overview of attempts to design novel formulations which could enhance its bioavailability is also presented. The review paper will help the scientist to exploit the drug to its optimum, which will help to overcome the challenges faced during its design and developmental stages.

摘要

由于具有多种治疗作用,白花丹素在研究中受到了广泛关注。它是从不同植物科(如白花丹科、茅膏菜科和柏科)获得的次生代谢产物。对白花丹素的各种研究表明,它是治疗癌症、糖尿病、疟疾、细菌感染和控制心血管疾病等慢性疾病的天然礼物。然而,将白花丹素开发为治疗剂存在几个挑战。首先也是最重要的是其有限的溶解度和口服生物利用度。第二个限制是它的毒性。白花丹素有一个狭窄的治疗窗口,文献表明该化合物在动物中有中等毒性。然而,数据不足以证明白花丹素对人类不安全。尽管白花丹素有许多治疗益处,但它仍然未被人类开发利用。因此,需要对其毒性、药理学和安全性进行系统评价。这项综述工作表明了通过研究证明的治疗应用的深度、其不同的分离和分离化学成分的模式及其修饰。还通过对接研究呈现了对有前途的治疗靶点的全面审查。还回顾了从植物中定量测定白花丹素的不同方法。还介绍了设计可提高其生物利用度的新型制剂的尝试。该综述文章将帮助科学家充分利用该药物,这将有助于克服在其设计和开发阶段面临的挑战。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验